Alnylam Pharmaceuticals, based in Cambridge, MA, is a leading RNAi therapeutics company that has revolutionized the field of medicine. Their pioneering science and commitment to patients have resulted in the development of a new class of medicines that have the potential to improve the lives of people worldwide. By harnessing the power of RNA interference, their innovative RNAi therapeutics can silence or turn off specific disease-causing genes, offering hope for longer, healthier, and fuller lives. With a deep pipeline of investigational RNAi therapeutics, Alnylam Pharmaceuticals is at the forefront of changing the way diseases are treated. Their technology has the ability to silence virtually any gene in the genome, opening up possibilities for treating a wide range of diseases. As a company dedicated to innovation and leadership in RNAi, Alnylam Pharmaceuticals is committed to making a broad impact by addressing complex health and societal challenges, going beyond rare diseases to improve the lives of millions.Generated from the website